Steinbeck Julius A, Studer Lorenz
The Center for Stem Cell Biology, Sloan-Kettering Institute for Cancer Research, 1275 York Avenue, New York, NY 10065, USA; Developmental Biology Program, Sloan-Kettering Institute for Cancer Research, 1275 York Avenue, New York, NY 10065, USA.
The Center for Stem Cell Biology, Sloan-Kettering Institute for Cancer Research, 1275 York Avenue, New York, NY 10065, USA; Developmental Biology Program, Sloan-Kettering Institute for Cancer Research, 1275 York Avenue, New York, NY 10065, USA.
Neuron. 2015 Apr 8;86(1):187-206. doi: 10.1016/j.neuron.2015.03.002.
Stem cell-based therapies hold considerable promise for many currently devastating neurological disorders. Substantial progress has been made in the derivation of disease-relevant human donor cell populations. Behavioral data in relevant animal models of disease have demonstrated therapeutic efficacy for several cell-based approaches. Consequently, cGMP grade cell products are currently being developed for first in human clinical trials in select disorders. Despite the therapeutic promise, the presumed mechanism of action of donor cell populations often remains insufficiently validated. It depends greatly on the properties of the transplanted cell type and the underlying host pathology. Several new technologies have become available to probe mechanisms of action in real time and to manipulate in vivo cell function and integration to enhance therapeutic efficacy. Results from such studies generate crucial insight into the nature of brain repair that can be achieved today and push the boundaries of what may be possible in the future.
基于干细胞的疗法对于许多当前具有毁灭性的神经疾病具有巨大的前景。在获取与疾病相关的人类供体细胞群体方面已经取得了实质性进展。相关疾病动物模型中的行为学数据已经证明了几种基于细胞的方法的治疗效果。因此,目前正在开发符合cGMP标准的细胞产品,用于某些疾病的首次人体临床试验。尽管具有治疗前景,但供体细胞群体的假定作用机制往往仍未得到充分验证。这在很大程度上取决于移植细胞类型的特性和潜在的宿主病理学。现在已经有几种新技术可用于实时探究作用机制,并操纵体内细胞功能和整合以提高治疗效果。这些研究结果为当今可以实现的脑修复的本质提供了至关重要的见解,并拓展了未来可能实现的边界。